Cantor Fitzgerald Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $65

Cantor Fitzgerald analyst Prakhar Agrawal maintains $Structure Therapeutics(GPCR.US)$ with a buy rating, and maintains the target price at $65.According to TipRanks data, the analyst has a success rat

Futu NewsJul 1 20:31 · Ratings

Analysts Offer Insights on Healthcare Companies: PTC Therapeutics (PTCT), Structure Therapeutics, Inc. Sponsored ADR (GPCR) and UnitedHealth (UNH)

TipRanksJul 1 20:10

Jefferies Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $79

Jefferies analyst Roger Song maintains $Structure Therapeutics(GPCR.US)$ with a buy rating, and maintains the target price at $79.According to TipRanks data, the analyst has a success rate of 30.2% an

Futu NewsJun 28 20:33 · Ratings

BMO Capital Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $100

BMO Capital analyst Evan Seigerman maintains $Structure Therapeutics(GPCR.US)$ with a buy rating, and maintains the target price at $100.According to TipRanks data, the analyst has a success rate of 4

Futu NewsJun 27 19:31 · Ratings

Pfizer's CEO announced the development of three new weight loss drugs, one of which is not a GLP-1 medication.

Pfizer's (PFE.US) CEO, Albert Bourla, said that the pharmaceutical company is testing three new weight loss drugs.

Zhitong FinanceJun 25 20:05

Goldman Sachs and Cantor Fitzgerald have a tacit agreement that the monopoly of "Norris" in the weight loss drug market is difficult to change.

Two top Wall Street analysts have reached a consensus, emphasizing that global weight loss drug market leaders "Novo" may continue to dominate the highly profitable weight loss drug market.

Zhitong FinanceJun 24 09:39